▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #373 by analyst upside · 2026-09-27
XFOR
X4 Pharmaceuticals, Inc.
Healthcare · Market Cap $298M · P/E 2.2x
ANALYST PRICE TARGET
+285.4%
implied upside to consensus target
Current Price $3.01
Consensus Target $11.6
Bull Target $13.0
Bear Target $10.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
5
Hold
0
Sell
0
52-Week Low $2.8
52-Week High $4.83
YTD Return -22.6%
FUNDAMENTALS
Market Cap $298M
P/E Ratio (TTM) 2.2x
Forward P/E N/A
EPS (TTM) $1.38
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $16M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.8
52-Week High $4.83
Current Price $3.01
Bear Target $10.0
Bull Target $13.0
● Now $3.01 ● Target $11.6
TRADING DATA
Avg Volume 796K
YTD Return -22.6%
Analyst Count 5
Consensus Buy
Upside to Target +285.4%
Last Updated 2026-09-27

ANALYST SUMMARY

X4 Pharmaceuticals, Inc. (XFOR) is currently trading at $3.01 with a Wall Street consensus price target of $11.6, implying potential upside of 285.4% over the next 12 months. 5 analysts currently cover XFOR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $13.0, while the most cautious has a target of $10.0.

XFOR operates in the Healthcare sector with a market capitalisation of $298M. The stock is down 22.6% year-to-date and is currently trading near the lower end of its 52-week range of $2.8 – $4.83.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for XFOR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo ● Initiated
Overweight 2026-07-10 Building track record
Leerink Partners ● Initiated
Outperform 2026-06-02 29% win rate (7 calls)
Guggenheim ● Initiated
Buy 2026-03-09 62% win rate (8 calls)
Stifel - Reiterated
Buy → Buy 2025-12-05 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-11-10 31% win rate (48 calls)
Stifel - Reiterated
Buy → Buy 2025-08-29 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-08-13 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-05-02 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
14/30
Consensus clarity
10/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →